

GRANTS AND BURSARIES								
APRIL 1, 2009 - MARCH 31, 2010								
NAME	AGENCY	TITLE	External Grants	Career Awards	Postgrad & Fellow Awards	Industrial Contracts	Clinical Research Awards	Foundation
JGH Totals (External grants include career awards)			25 900 139			5 206 454		6 238 185
Operating Grants & Awards								
Medicine Totals (External grants include career awards, fellows)			20 344 439			4 681 619	106 664	3 100 159
Medicine - Totals			18 833 954	1 510 485				
Alaoui Jamali	Cancer Research Society	Focal Adhesion Regulators of Early Invasive Breast Cancer: Therapeutic Targeting in Preclinical Models and Clinical Validation in Progressive Breast Cancer.	150 000					
Alaoui Jamali	National Cancer Institute of Canada	Canadian Breast Cancer Research Initiative - Molecular and Functional Studies of Focal Adhesion Protein Trafficking and Turnover in Invasive Cancer Cells.	95 625					
Alaoui Jamali	Canadian Institutes for Health Research	CIHR -Alaoui-Jamal- Molecular and Translational	100 000					
Alaoui Jamali	Canadian Institutes for Health Research	Discovery and Validation of Pharmacological Probes for Understanding Protein-protein Interactions of Focal Adhesion Signaling in Invasive Cancer Cells.	87 252					
Alaoui Jamali	Cancer de la prostate Canada	Targeting a Novel Heme Oxygenase Signaling Pathway in Prostate Cancer and Therapeutic Applications.	30 000					
Aloyz R.	Fonds de la recherche en santé du Québec	Programme du Fonds d'innovation Pfizer-FRSQ.	23 000					
Aloyz R.	National Cancer Institute of Canada	CBCRA - Toward the Biological Treatment of BRCA1-related Breast Cancer: EGF, EGFR and Tyrosine Kinase Inhibitors.	26 534					
Autexier C.	Canadian Institutes for Health Research	CIHR- Autexier C. - MOP-81215-telo & cancer	48 866					
Autexier C.	Canadian Institutes for Health Research	Investigation of Telomere and Telomerase Regulation by Associated Proteins and in Primary Malignant Lymphocytes.		35 000				
Autexier C.	Canadian Institutes for Health Research	Supramolecular Complexes as G-quadruplex Binders: Towards Effective Telomerase Inhibition.	11 583					
Autexier C.	Canadian Institutes for Health Research	Telomerase Processivity and Telomere Length Regulation.		35 000				
Baron M.	Canadian Institutes for Health Research	A New Emerging Team: the Canadian Scleroderma Research Group.	179 173					
Baron M.	Canadian Institutes for Health Research	CIHR-Baron-a Randomized Double Blind PLA	98 795					
Baron M.	Canadian Institutes for Health Research	CIHR-Canadian Scleroderma Research Group	25 000					
Baron M.	Canadian Institutes for Health Research	Strategic Training Initiative - Canadian Scleroderma Research Group.	300 000					
Baron M.	Scleroderma Society of Canada	Canadian Scleroderma Research Group.	211 945					
Batist G.	Amgen Canada Inc.	Colorectal Cancer New Treatments (AMG)	70 000					
Batist G.	Fonds de la recherche en santé du Québec	Programme du Fonds d'innovation Pfizer-FRSQ	375 000					
Batist G.	Fonds de la recherche en santé du Québec	Réseau de la recherche sur le cancer du FRSQ - Axe: Thérapies expérimentales.	55 000					
Batist G.	Fonds de la recherche en santé du Québec	Réseau provincial - Cancer.	55 000					
Batist G.	Sir Mortimer B. Davis Jewish General H	Segal Research Coordination	104 000					
Batist G.	Canadian Institutes for Health Research	EPHB2, a Novel Target for Gamma-secretase Inhibitors (GSIS) in Cancer Therapy.	124 998					
Batist G.	Canadian Institutes for Health Research	Montreal Centre for Experimental Therapeutics in Cancer.	84 937					
Beitel L.	Kennedy Disease Association	Investigating the Mechanisms Contributing to Kennedy's Disease: Polyglutamine-expanded Androgen Receptors and U-p System	10 716					
Beland F	Ministère de la santé/des serv sociaux	Frêle: Fragilité, une étude longitudinale des expressions et accès, utilisation et coûts des services sociaux et de santé associés aux profils et trajectoires de fragilité.	179 026					
Beland F	Canadian Institutes for Health Research	CIHR Team in Frailty and Aging.	792 220					
Beland F	Canadian Institutes for Health Research	Gestion optimale des maladies chroniques chez les personnes âgées: hôpital et services de proximité	15 000					
Beland F	Institut de recherche en santé publique	Models of Chronic Disease	15 000					
Bergman H.	Fonds de la recherche en santé du Québec	Réseau Québécois de recherche sur le vieillissement.	900 000					
Bergman H.	La Régie - Santé et des serv. soc.	Plan d'action national sur la maladie d'Alzheimer et les maladies s'y apparentant.	(14 168)					
Bergman H.	National Cancer Institute of Canada	A Novel Way of Assessing Health Vulnerability in Older Newly Diagnosed Cancer Patients: a Prospective Pilot Study		10 703				
Bergman H.	Fondation Gustav Levenschi	Canadian Initiative on Frail Older Persons.	58 500					
Bergman H.	Regroupement Compagn. Fond. et particul.	CIHR - the Frailty Data (FRDARA) Project.	1 400					
Bergman H.	Acker Finley Inc.	Ronald Oberlander Fellow.	40 000					

Blank V.	McGill University	McGill University - (6305)- Infracture - Role of CNC and MAF Factors in Mammalian Differentiation and Oncogenesis.	8 679					
Blank V.	National Cancer Institute of Canada	The Role of CNC Transcription Factors in Carcinogenesis.		22 500				
Blank V.	Canadian Institutes for Health Research	Analysis of Novel Regulators of Erythroid Differentiation.		22 000				
Blank V.	Canadian Institutes for Health Research	Role of NRF3 Transcription Factor in Lymphomagenesis.	49 707					
Blostein M.	Canadian Hemophilia Society	Use of Amphipathic Helical Peptides Coupled to Nanofibrous Microspheres to Control Hemorrhagic External Bleeding in Hemophiliacs	65 000					
Blostein M.	Heart & Stroke Foundation Quebec	Physiology of GAS6-AX1 Interaction in Endothelial Cells.	17 000					
Blostein M.	Public Works & Government Services Canada	Development and Optimization of Hemostatic Peptides for Hemorrhage Control on Battlefield.	41 903					
Blostein M.	Canadian Institutes for Health Research	A Double-blind Randomized Control Trial of Post-operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism.	3 314					
Blostein M.	Canadian Institutes for Health Research	CIHR Team Grant in Venous Thromboembolism.	30 000					
Blostein M.	Canadian Institutes for Health Research	Role of GAS6 in Vascular Biology	24 487					
Blostein M.	London Health Sciences Centre	IRC-low Molecular Weight	1 326					
Cen S.	Canadian Institutes for Health Research	The Potential of Apobec3g in the Development of a Novel Anti-HIV-1 Therapeutic.	109 331					
Chalifour L.	Heart & Stroke Foundation Quebec	Role of Gender-dependent Differences in Calcium Homeostasis Protein Expression in Dictating the re sponse to catecholamine stress.	23 000					
Chalifour L.	Canadian Institutes for Health Research	Steroidial Hormone Programming in Heart.	102 062					
Chertkow H.	Alzheimer Society of Canada	Longitudinal Study of the Neuropsychological, Neuroanatomical and Salivary Cortisol Profiles of Individuals with Mild Cognitive Impairment.		10 265				
Chertkow H.	Alzheimer Society of Canada	Transcranial Magnetic Stimulation as a Treatment for Anemia in Patients with Alzheimer's Disease.		9 500				
Chertkow H.	Université de Montréal	Axe Cognition / RQRV/u.mtl	10 875					
Chertkow H.	Canadian Institutes for Health Research	CIHR-Dr. Kenneth Rockwood - Dalhousie University (Nova Scotia) - Create the Canadian Dementia Knowledge Translation Network (CDKTN).	75 735					
Chertkow H.	Canadian Institutes for Health Research	Cognitive Neuroscience Studies of Language in Alzheimer's Disease.	149 843					
Chertkow H.	Canadian Institutes for Health Research	Establishing Prognostic Subgroups in Mild Cognitive Impairment.	126 503					
Cohen A.	CUSM Centre Universit. de Santé McGill	Alain Bitton - Univ. Mtl. - NIH - IBD Genetics Consortium.	1 600					
CohenR.	National Cancer Institute of Canada	Palliative Care.	11 215					
CohenR.	Canadian Institutes for Health Research	Addressing the Needs of Culturally Diverse Family Care givers in Palliative Care.		35 000				
CohenR.	Canadian Institutes for Health Research	Family Care giving in Palliative and End-of-life Care: a New Emerging Team.	21 700					
CohenR.	Canadian Institutes for Health Research	Knowledge Transfer for Family Care giving in P/EOL Care	40 000					
Eisenberg M.	Heart & Stroke Foundation Quebec	Prix John J. Day & Prix Feifer.		18 250				
Eisenberg M.	Canadian Institutes for Health Research	CIHR-eisenberg-the Efficacy of Weight Loss	100 000					
Eisenberg M.	Canadian Institutes for Health Research	The Efficacy of Popular Diets: a Systematic Review and Hierarchical Bayesian Meta-analysis.	50 300					
Eliopoulos N.	RoFarFoundation for Anemia Research	Cell and Gene Therapy with Erythropoietin-secreting Marrow Stem Cells for Kidney Repair.	252 160					
Ernst P.	Canadian Institutes for Health Research	Bronchodilators and the Risk of Cardiovascular Outcomes in COPD: Assessing Risk Using New Methodological Approaches.						
Foulkes W.	Fonds de la recherche en santé du Québec	Réseau de recherche sur le cancer (Axe banque de tissus et de données).	30 000					
Foulkes W.	National Cancer Institute of Canada	CBCRA - Toward the Biological Treatment of Brca1-related Breast Cancer: EGF, EGFR and Tyrosine Kinase Inhibitors.	35 275					
Foulkes W.	US Army Medical Research & Material Comm	Exploring the Pathogenic and Therapeutic Implications of Aberrant Splicing in Breast Cancer.	117 334					
Foulkes W.	Susan G. Komen Breast Cancer Foundation	Susan G. Komen Breast Cancer Foundation Grant with Dr. Jun Zhu - Systematic Characterization of Dasatinib Sensitivity and Resistance in BRCA Cells.	85 500					
Foulkes W.	Canadian Gene Cure Foundation	Correcting Splicing in He Mismatch Repair Gene PMS2 as a Model for Therapy of Genetic Diseases.	70 000					
Friedman G.	CusmCentre Universit.De Sante McGill	CIHR-implementation of Consensus Recommendations in the Management of Canadian Patients with non Var	11 210					
Galipeau J.	Heart & Stroke Foundation Canada	Cardiovascular and Respiratory Stem Plasticity - Care Project.	50 000					
Galipeau J.	Réseau des centres d'excellence fédéral	PHACET -Continuation.	59 498					
Galipeau J.		Stem Cell-based Gene Transfer of Hemophilia a (CT3).	60 000					

Galipeau J.	Fonds de la recherche en santé du Québec	Programme des réseaux de recherche FRSQ - Réseau Québécois de thérapie cellulaire et tissulaire (the cell).	166 667					
Galipeau J.	Fonds de la recherche en santé du Québec	Régroupement stratégique Québécois pour la recherche et le développement de la thérapie cellulaire et génétique pour les maladies hémovasculaires.	300 000					
Galipeau J.	National Cancer Institute of Canada	McMaster Univeristy - Jonathan Bramson - Cancer Immunotherapy Program.	105 754					
Galipeau J.	Canadian Institutes for Health Research	Cardiovascular and Respiratory Stem Plasticity - Care Project.	100 000					
Galipeau J.	Canadian Institutes for Health Research	Détermination des processus moléculaires impliqués dans l'immunomodulation par les cellules stromales mésenchymateuse issues de la moelle osseuse.		35 000				
Galipeau J.	Canadian Institutes for Health Research	Drug Resistance Gene Transfer into Bone Marrow to Protect from the Hematopoietic Toxicity of Chemotherapy.	184 074					
Gatignol A.	Canadian Institutes for Health Research	CIHR-Gatignol-virus Cell Interactions	24 320					
Gatignol A.	Canadian Institutes for Health Research	Developmental and Characterization of Antiretroviral Rnas To Target HIV Replication.		35 000				
Gatignol A.	Canadian Institutes for Health Research	Effects of HIV-1 Infection on Interactions Between Protein Components of the RNA Interference Pathway.		7 292				
Gatignol A.	Canadian Institutes for Health Research	Exploring Interactions Between HIV and the RNA Interference Pathway.	123 557					
Gatignol A.	Canadian Institutes for Health Research	Regulation of HIV-1 Replication by RNA Interference and Proteins of the RISC.		50 000				
Greenaway C.	Fonds de la recherche en santé du Québec	Une étude de Population sur l'hépatite virale chez les immigrants: fardeau, coûts et détermination de l'intervention Optimale.	61 811					
Greenaway C.	Université de Montréal	Metropolis 2008 - Cost-effectiveness Analysis to Determine The Optimal Strategy to Prevent Measles, Mumps, Rubella, Diphtheria and Tetanus in the Immigrant Population.	2 400					
Hiscott J.	National Cancer Institute of Canada	Molecular Mechanisms Regulating T Cell Leukemogenesis by HTLV-1 Tax Protein.	182 000					
Hiscott J.	The Ottawa Heart Research Institute Corp	Canadian Oncolytic Virus Consortium.	160 125					
Hiscott J.	Canadian Institutes for Health Research	Regulation of Cytokine Gene Expression by the IRF Transcription Factors.	176 816					
Hiscott J.	Canadian Institutes for Health Research	Regulation of Toll-like Receptor-independent and Independent Antiviral Pathways During de Novo HIV-1 Infection.	159 526					
Hiscott J.	Canadian Institutes for Health Research	Role of Toll-like Receptors (TLRS) in the Human Immunodeficiency Virus-1 (HIV-1) Replication in Human Primary Macrophages.		35 000				
Hoffer J.	Lotte & John Hecht Memorial Foundation	Study - Intravenous Vitamin C in Combination with Chemotherapy in Lung Cancer Patients.	50 000					
Honos G.	Canadian Institutes for Health Research	CIHR - Astronomer Study - the Effect of Cholesterol Lowering on Progression of Aortic Stenosis in Patients With Mild to Moderate Aortic Stenosis.	12 490					
Hudson M.	Fonds de la recherche en santé du Québec	Etablissement de jeune chercheur - développement et validation d'instruments pour étudier la sclérodémie et l'arthrite Inflammatoire débutante.	10 000					
Hudson M.	Canadian Institutes for Health Research	Development and Validation of a Patient-assessed Disease Activity Index in Systemic Sclerosis.	87 208					
Jagoe T.	Canada Foundation For Innovation	Mechanism of Muscle Wasting in Clinical Cancer Cachexia: New Experimental Approaches and Models for Testing Anti-cachexia Therapies.	140 138					
Kahn S.	National Institutes of Health (Usa) Ni	Suresh Vedantham -University of McMaster - Pharmacomechanical Catheter-directed Thrombolytic for Acute DVT-attract Trial.	32 441					
Kahn S.	Heart And Stroke Foundation of Ontario	P. Wells - HSFO - Development and Validation of Clinical Prediction Rules for Bleeding for Patients on Anticoagulant Therapy for Venous Thromboembolism.	1 167					
Kahn S.	Heart And Stroke Foundation of Ontario	Thrombosis in Family Members of Patients with Unprovoked Venous Thromboembolism.	500					
Kahn S.	The Ottawa Heart Research Institute Corp	CIHR - Further Innovation in Thrombosis Research.	28 403					
Kahn S.	The Ottawa Heart Research Institute Corp	CIHR 524e-CVD-9101-004 - TIPPS (Thrombophilia in Pregnancy Prophylaxis Study): a Multicenter, Multinational Randomized Control Trial of Prophylactic Low Molecular Weight Heparin (LMWH) in High Risk Pregnant Thrombophilic Women.	1 800					
Kahn S.	Canadian Institutes for Health Research	CIHR Café Scientific - Lots about Clots: Deep Vein Thrombosis and Pulmonary Embolism	3 000					
Kahn S.	Canadian Institutes for Health Research	CIHR-Kahn-evaluation of Interventions Fo	90 020					

Kahn S.	Canadian Institutes for Health Research	Dalhousie University - Extended Prophylaxis Comparing Low Molecular Weight Heparin (LMWH) to Aspirin in Total Hip Arthroplasty (EPCAT Study).	42 000					
Kahn S.	Canadian Institutes for Health Research	Prospective Evaluation of Long-term Outcomes after Pulmonary Embolism: the Elope Study.	156 387					
Kahn S.	Lawson Health Research Institute	A Prospective Study of Upper Extremity Deep Vein Thrombosis to Determine the Prevalence of Post-thrombotic Syndrome in Patients Managed with Anticoagulation.	4 500					
Karaplis A.	McGill University	CIHR Strategic Training Program.		20 000				
Karaplis A.	Public Works & Government Services Canada	PTHRP Expression and Osteoblast Apoptosis in Microgravity-induced Osteoporosis.	40 605					
Karaplis A.	Canadian Institutes for Health Research	CIHR-group in Medical Genetics-rima Rozen.	6 000					
Karaplis A.	Canadian Institutes for Health Research	Molecular Genetics of Calcitropic Peptides.	52 811					
Karaplis A.	Canadian Institutes for Health Research	PTHRP and Osteoblast Biology: Relevance to Osteoporosis.	119 085					
Kleiman L.	National Institutes of Health (USA)	Development of the GAG/LYRA Interaction as a Target for Anti-HIV Therapy.	489 492					
Kleiman L.	Canadian Institutes for Health Research	Annealing of Primer TRNA LYS3 to Genomic RNA in HIV-1.	145 084					
Kleiman L.	Canadian Institutes for Health Research	Formation of the TRNALYS Packaging Complex in HIV-1.	127 026					
Langleben D.	McGill University	Research in Heart Diseases.	36 875					
Leblanc A.	Institut universitaire de geriatric de Montréal	Nouveau modèle de la maladie d'Alzheimer dans le poisson zèbre	8 000					
Leblanc A.	Canadian Institutes for Health Research	IRSC-MOP-81146-Neuronal	82 279					
Leblanc A.	Canadian Institutes for Health Research	Detection of Tau Cleaved by Caspase-6 in the Cerebrospinal Fluid of Individuals with Age-related Cog	49 110					
Leblanc A.	Canadian Institutes for Health Research	Regulation of Prion Protein Expression, Trafficking and Function	26 534					
Leblanc A.	Canadian Institutes for Health Research	Role of Caspases in Human Neuronal Cell Death and in Alzheimer's Disease.	41 139					
Leblanc A.	Canadian Institutes for Health Research	Role of Normal Cellular Prion Protein Against BAD-mediated Cell Death.	(25 000)					
Leblanc A.	Canadian Institutes for Health Research	Structure-function Analyses of Caspase-6.	25 000					
LEHOUX S.	Secrétariat des chaires de rech. du Can.	CRC Chair - Régulation de l'expression du récepteur AT1 de l'angiotensine par la contrainte de cisaillement: Rôle dans l'athérosclérose		99863				
Lehoux S.	McGill University	McGill University - CFI-CRC-vascular Signalling and Function.	211 160					
Lehoux S.	Centre Hospitalier Unir de Quebec(CHUQ)	Transformation des EPC pour Stopper la Resténose	20 700					
Lehoux S.	Canadian Institutes for Health Research	CIHR-athero-protective Shear Stress Signalling in the Vasculature	25 546					
Liang C.	Canadian Foundation For Aids Research	Understanding the Anti-HIV-1 Activity of the Insulin-like Growth Factor II mRNA Binding Protein 1.	80 000					
Liang C.	Canadian Institutes for Health Research	CIHR-liang C.-cgm-98426/cheng Cicky	17 500					
Liang C.	Canadian Institutes for Health Research	Exploring the Involvement of RNA Helicases in HIV-1 Replication.	111 303					
Liang C.	Canadian Institutes for Health Research	Fragile X Mental Retardation Protein Targets HIV-1: from Fragile X Syndrome to Aids.	104 017					
Liang C.	Canadian Institutes for Health Research	Studying the Antiviral of Bone Marrow Stromal Cell Antigen 2 and the Countering Mechanism from HIV-1 VPU.	72 135					
Liang C.	Canadian Institutes for Health Research	Towards a Better Understanding of HIV-host Cell Interactions: Targeting Virus Production and Transmission For Intervention.	32 250					
Lin R.	Canadian Institutes for Health Research	Hepatitis C Virus Replication and Interferon Signalling.	142 927					
Lin R.	Canadian Institutes for Health Research	Small Molecule Agonists of the RIG-I Pathway as Innate Stimulatory Agents Against Influenza Virus Infection.	66 400					
Mann K.	National Institutes of Health (NIH)	The Role of LXR/RXR Heterodimers in Arsenic-induced Atherosclerosis.	163 926					
Michel C.	Aventis Pharma Canada	Heart Failure Clinic Equipment Donation.	75 170					
Michel C.	Canadian Institutes for Health Research	Étude du suivi des patients vus en urgence hospitalière pour insuffisance cardiaque congestive (IC): comparaison de ceux qui sont orientés vers les cliniques spécialisées et de ceux qui ne le sont pas.	1 000					
Miller W.	AACR	Targeting EIF4E with Ribavirin in Poor Prognosis Breast Cancer	52 298					
Miller W.	McGill University	McGill Integrated Cancer Research Training Program	60 000					
Miller W.	National Cancer Institute of Canada	The Role of Ross in the Enhanced Tumor Specificity of Aresnice When Combined with the Vitamin E-derivative Trolox.	93 227					
Miller W.	CUSM Centre Universitaire de santé McGill	CIHR - Brian Ward - Molecular Mechanisms of Retinoids as Anti-virals in Respiratory Virus Infections.	55 000					
Miller W.	Canadian Institutes for Health Research	Mechanisms of Anti-cancer Action of Arsenic and Antimony.	176 306					
Miller W.	Canadian Institutes for Health Research	Mechanisms of Response and Resistance to Retinoic Acid In Acute Promyelocytic Leukemia.	138 305					
Miller W.	Samuel Waxman Cancer Research	Development of Novel Anti-cancer Therapies Using Arsenic Trioxide.	48 364					

Miller W.	Terry Fox Research Institute	Translating Predictive and Prognostic Breast Cancer Biomarkers to the Clinic.	25 000					
Miller W.	The Cole Foundation	Cole Foundation Fellowship		23 333				
Mouland A.	Canadian Institutes for Health Research	Intéactions virus-hôte régulant le sort de l'ARN du VIH-1.		22 000				
Mouland A.	Canadian Institutes for Health Research	Studies on the Importance of Heterogeneous Nuclear Ribonucleoprotein A2 in the Cell-to-cell Transmission of HIV-1 in T Cells.		22 000				
Mouland A.	Canadian Institutes for Health Research	Viral-host Interactions Involved in Genomic RNA Encapsidation and Metabolism: Important Roles for Staufen and Associated Factors.	105 062					
Mouland A.	Canadian Institutes for Health Research	Virus-host Interactions and HIV-1 Pathogenesis: Studies on HNRNP A2-mediated HIV-1 RNA Trafficking.	109 807					
Muanza T.	Fonds de la recherche en santé du Québec	Subvention d'établissement de jeune chercheur clinicien.		10 000				
Panasci L.	National Cancer Institute of Canada	Sorafenib in Breast Cancer: a Laboratory-based Approach For a Rational Clinical Development. (Post-MD Research Fellowship).		35 625				
Panasci L.	Canadian Institutes for Health Research	CIHR/r&d -Wyeth Pharmaceuticals Research Program - Synergistic Effect of DNA-PK Inhibitors in the Treatment Of Colon Cancer.		45 000				
Pantopoulos K	Fondation Canadienne du Foie	The Role of Soluble Hemojuvelin in Hepatic Hcpidin Regulation.		5 000				
Pantopoulos K	Natural Sci & Engineering Res Council	NSERC-pantopoulos-natural Sciences/McGill	55 822					
Pantopoulos K	Canadian Institutes for Health Research	Iron Metabolism in Health and Disease: the Ire/IRP System And Beyond.	128 656					
Pantopoulos K	Canadian Institutes for Health Research	The Role of Soluble Hemojuvelin in Systemic Iron Homeostasis.	173 047					
Pantopoulos K	Societe Canadienne Du Cancer	Iron Regulatory Protein 1: Identification And Characterization of Interacting Partners.	30 000					
Paudel H.	Parkinson's Foundation of Canada	Parkinson's Disease.		43 333				
Paudel H.	McGill University	Phosphorylation of Protein Phosphatase 1 During Neuronal Differentiation.	54 313					
Paudel H.	Alzheimer Society of Canada	ASC/FRSQ Award - Pathogenic Tau Mutations and Neurodegeneration.		18 861				
Paudel H.	Alzheimer Society of Canada	EGR-1 and Alzheimer's Disease	56 250					
Paudel H.	Alzheimer Society of Canada	Tau Protein and NFT-pathology of Ad.	18 750					
Paudel H.	Canadian Institutes for Health Research	Tau Protein and Alzheimer's Disease.	119 809					
Pollak M.	National Institutes of Health (NIH)	Fred Hutchinson - Mechanism of Energy Balance and Cancer Prevention.	83 316					
Pollak M.	National Institutes of Health (NIH)	MD Anderson Cancer Centre - Biology of the Prostate Cancer Prevention Trial (PCPT): Project 3 - Insulin like Growth Factor Axis and Insulin.	447 459					
Pollak M.	National Institutes of Health (NIH)	NIH - IGF and Breast Cancer.	484 015					
Pollak M.	National Institutes of Health (NIH)	PLCO-growth Factor Study and Obesity Related Biomarker Study.	34 320					
Pollak M.	National Institutes of Health (NIH)	University of Medicine & Dentistry of New Jersey - Aviv Abraham - Leukocyte Telomere Dynamics, Gender, Menopause, Insulin Resistance and Survival.	19 250					
Pollak M.	National Cancer Institute of Canada	Canadian Breast Cancer Research Initiative - IGF and Insulin Signalling Pathways in Breast Cancer	170 903					
Pollak M.	National Cancer Institute of Canada	Canadian Breast Cancer Research Initiative - Modifiable Dietary Determinants of Levels of IGF-1, Insulin, and Risk Of Colorectal Cancer and Lethal Prostate Cancer.	138 627					
Pollak M.	National Cancer Institute of Canada	Dietary Factors Influencing IGF-signalling in Prostate Cancer.	106 477					
Pollak M.	Canadian Institutes for Health Research	China-Canada Collaborative Research to Investigate Applications of Metformin in Oncology.	9 500					
Pollak M.	Prostate cancer foundation	Prevention of Treatment and Disease-related Morbidity During Androgen Deprivation Therapy: a Multicenter Proposal.	109 000					
Pollak M.	Terry Fox Research Institute	Clinical Targeting of the IGF-1 / Insulin Signalling via The PI3K / AKT / MTOR Pathway to Treat Breast and Prostate Cancer	171 577					
Pollak M.	Provincial Health Services Authority	CPCRI - Does Insulin Resistance Increase Risk of Prostate Cancer? Assay Work. (NCIC with Richard G	36 394					
Pollak M.	University of Hawaii	Oth-pollak-nih-univ.hawaii-epidemiologic	7 665					
Pollak M.	Cancer de la prostate Canada	PTEN Loss and Energy Metabolism in Prostate Cancer.	30 000					
Ponka P.	Societe canadienne du sang	Chelation, Mobilization and Metabolism of Storage Iron.	33 170					
Ponka P.	Societe canadienne du sang	Iron Trafficking in Developing Red Cells.		45 000				
Ponka P.	Canadian Institutes for Health Research	Chelation, Mobilization and Metabolism of Storage Iron.	104 213					
Ponka P.	Canadian Institutes for Health Research	Regulation of Iron Metabolism and Heme Synthesis In Erythroid Cells.	128 495					
Richard S B.	Fonds de la recherche en santé du Québec	Etablissement de Jeune Chercheur - Epidemiologie Genetique des Fractures Osteoporotiques: des Genes de Susceptibilite Aux Populations Susceptibles.	10 000					
Richard S B.	Canadian Institutes for Health Research	Genetic Epidemiology of Osteoporotic Fractures. From Susceptibility Genes to Susceptible Populations.	118 850					

Richard S B.		Genetic Epidemiology of Osteoporotic Fractures: from Susceptibility Genes to Susceptible Populations.		28 333				
Richard S.	Cancer Research Society	Investigation of SAM68-like Mammalian Proteins, SLM-1 And SLM-2, in Human Cancers.	30 000					
Richard S.	Fonds de la recherche en santé du Québec	Lauréat des chercheurs nationaux du Québec 2007/2008 - Rôles des protéines KH liant l'ARN et la méthylation des arginines: implications pour la sclérose en plaques et le cancer.	20 000					
Richard S.	Multiple Sclerosis Society of Canada	Identification of the Quaking RNA Targets.		18 000				
Richard S.	Multiple Sclerosis Society of Canada	QKI Myelination.		18 000				
Richard S.	Multiple Sclerosis Society of Canada	Study Micro RNA and Quaking RNA Binding Protein Function on Oligodendrocyte Differentiation.		29 250				
Richard S.	Multiple Sclerosis Society of Canada	The Role of the Quaking Protein in Signal Transduction And RNA Metabolism.	53 180					
Richard S.	National Cancer Institute of Canada	NCIC-richard-#017119/dna-closed	34 310					
Richard S.	National Cancer Institute of Canada	The Role of Protein Demethylases in the DNA Damage Response.		(3 438)				
Richard S.	National Cancer Institute of Canada	The Role of the Quaking Ran Binding Proteins in Tumorigenesis.	123 000					
Richard S.	Canadian Institutes for Health Research	Arginine Methylase Prmt1 and Prmt6 in Cancer and Genomic Instability.	140 336					
Richard S.	Canadian Institutes for Health Research	Lysine Methylation of Non-histone Proteins.		31 778				
Richard S.	Canadian Institutes for Health Research	Role of the Star RNA Binding Protein Sam68 in Regulating Cell Migration and Proliferation in Cancer.	156 661					
Richard S.	Canadian Institutes for Health Research	The Role of Arginine Methylation Mre11 in Mediating the DNA Damage Response.	137 473					
Richard S.	Canadian Institutes for Health Research	The Role of Protein Demethylases in the DNA Damage Response.		45 000				
Richard S.	Fondation Canadienne pour l'innovation	McGill University - Imaging Spreading Initiation Centres (Sics) in Normal and Cancer Cells.	132 302					
Rudski L	Sir Mortimer B. Davis Jewish General H	Avi Shimony - Azrieli Fellow		50 000				
Schiffirin E.	Heart & Stroke Foundation Canada	At1 Receptors Are Essential in Aldosterone Signalling in VSMC and Impairment of EPCS Differentiation.		20 000				
Schiffirin E.	Heart & Stroke Foundation Canada	Remodelage des Artères de Petit et Gros Calibre dans l'insuffisance Rénale Chronique.		13 333				
Schiffirin E.	Heart & Stroke Foundation Canada	Role of P38 Map Kinase and Map Kinase-activated Protein Kinase 2 Pathway in Angiotensin II-induced Vascular Inflammation in Hypertension.		20 165				
Schiffirin E.	McGill University	Dean's Funds - Vascular Phenotype Infrastructure: Molecular and Cellular Mechanisms of Vascular Remodeling In Hypertension and Metabolic Syndrome.	89 500					
Schiffirin E.	Université de Montréal	Oth-schiffirin E-cartagene		189 838				
Schiffirin E.	Canadian Institutes for Health Research	CIHR-t-regulatory Cells and Vascular Injury in Hypertension		30 762				
Schiffirin E.	Canadian Institutes for Health Research	Role of Endothelin in Hypertension and Vascular Injury.		136 468				
Schiffirin E.	Canadian Institutes for Health Research	Vascular Remodeling in Hypertension: from Genes to Mice to Humans.		136 678				
Schiffirin E.	Canadian Institutes for Health Research	CRC/CIHR/Tier 1 - The Fate of Blood Vessels in Hypertension, Metabolic Syndrome, and Diabetes		199588				
Schipper H.	Grouping of Canadian Individuals	MKCF Research.	200 019					
Schipper H.	Canadian Institutes for Health Research	Role of Heme Oxygenase-1 in Aging and Parkinsonian Neural Tissues.	136 571					
Schipper H.	Chiltern Int. Ltd	A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Withdrawal-design Study To Assess the Clinical Effect of Droxidopa in Subjects With Primary Automatic Failure, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neurop	21 832					
Sheppard R.	Institut De Cardiologie De Montreal	Atacand - Effects of Ace Inhibitor plus High Dose Cadesartan BNP and Inflammation in Patients with LV Dysfunction: Impact of Reninangiotensin-aldosterone System Genetic Poly Morphysims - the CANDIID II Trial.	7 849					
Sheppard R.	Institut De Cardiologie De Montreal	Dr. Jean Rouleau - Carress - Cardioresnal Rescue Study in Acute Decompensated Heart Failure.	8 000					
Suissa S.	Canadian Institutes for Health Research	CIHR-suissa-the Use of Atypical Antipsyc	100 000					
Tagalakis V	Heart & Stroke Foundation Quebec	Screening for Previously Undiagnosed Malignancy in Patients with Unprovoked Venous Thromboembolism: a Randomized Controlled Trial Using a Comprehensive Computed Tomography of the Abdomen/pelvis.	9 750					
Tagalakis V	Canadian Institutes for Health Research	The Effect of Warfarin Use on the Risk of Prostate Cancer Death.	60 000					
Tagalakis V	Eisai Research Institute	Dalteparin Sodium Injection (Fragmin), Multi-center, Open Label, Single-arm, Controlled Long-term (53 Weeks) Study For Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Thromboembolism.	15 406					

Thombs B.	Fonds de la recherche en santé du Québec	Développement et validation d'un système intégré pour évaluer la fatigue liée à la sclérodémie.	65 204					
Thombs B.	Fonds de la recherche en santé du Québec	Établissement de jeune chercheur - la sclérodémie: un programme d'étude portant sur l'expérience de la maladie selon la perspective des patients.		15 000				
Thombs B.	American College of Rheumatology	ACR Research and Education Foundation ARHP Investigator Award.	53 583					
Thombs B.	Alliance can la rech. sur cancer sein	Depression of Distress Screening and Patient Outcomes in Breast Cancer: a Systematic Review.	50 000					
Thombs B.	Canadian Institutes for Health Research	CIHR-depression Screening and Patient Outcomes in Pregnancy and Postpartum: a Systematic Review	60 000					
Thombs B.	Canadian Institutes for Health Research	CIHR-thombs-depression Screening and Pat	97 766					
Thombs B.	Canadian Institutes for Health Research	Development and Validation of a Pruritus Measure for Patients with Systemic Sclerosis.		4 950				
Thombs B.	Canadian Institutes for Health Research	Development and Validation of Measures of Body Image Distress in Systemic Sclerosis.		17 500				
Thombs B.	Canadian Institutes for Health Research	Joint Patient - Researcher Meeting to Interpret and Plan For Dissemination of Patient Survey Results.	11 240					
Thombs B.	Canadian Institutes for Health Research	Prevalence and Clinical Correlates of Female Sexual Dysfunction in Scleroderma.		17 500				
Tischkowitz M.	Susan G. Komen Breast Cancer Foundation	PALB2 - A New Hereditary Cancer Gene: Implications for Treatment.	122 366					
Trifiro M.	Prostate Cancer Research Found. of Canada	Isolation and Characterization of Active Ar-transcriptional Complexes - New Therapeutic Targets.	30 000					
Trifiro M.	McGill University	McGill / GSK Lecture on Metabolism.	5 000					
Trifiro M.	McGill University	Thyroid Tumor Study Group-ent/thyroid.	40 640					
Trifiro M.	McGill University	Vamsy Chodavarapu - FQRNT # PR-133597 - Bioseneurs génétiquement modifiés à haute sélectivité et sensibilité.	41 000					
Trifiro M.	National Cancer Institute of Canada	NCIC-trifiro - #017476/CAG	34 370					
Trifiro M.	Canadian Institutes for Health Research	CIHR - Rima Rozen - MRC Group in Medical Genetics.	(19 130)					
Wainberg M.	Fonds de la recherche en santé du Québec	Analyse Moléculaire.	20 000					
Wainberg M.	Fonds de la recherche en santé du Québec	Coordination réseau sida et maladies infectieuses.	47 500					
Wainberg M.	Fonds de la recherche en santé du Québec	Réseau sida et maladies infectieuses.	87 000					
Wainberg M.	Laboratoire De Santé Publique	Phase 2 - Infrastructures pour la recherche sur l'infection au VIH: Doter le Québec et le Canada d'infrastructures pour un vaccin et des thérapies Contre le VIH et l'hépatite C.	196 842					
Wainberg M.	Canadian HIV Trials Network	CTN Post-doctoral Fellowship Award.		25 000				
Wainberg M.		Oth-Winberg M.-sloan R-ccrs Co-receptor	50 000					
Wainberg M.	University of Michigan	James Koopman - NIH-HIV Risk Dynamics, Genetic Patterns And Control.	202 563					
Wainberg M.	Canadian Institutes for Health Research	Defining Effective Anti-viral Combinations in Order to Decrease the Sexual Transmission of HIV.		35 000				
Wainberg M.	Canadian Institutes for Health Research	Development of New Strategies to Target HIV Replication And Stimulate Anti-HIV Post-exposure Immunity.	10 000					
Wainberg M.	Canadian Institutes for Health Research	Étude de l'impact des nouvelles molécules antirétrovirales sur les sous-types non B de VIH-1, l'importance des nouvelles mutations et des populations minoritaires portant des mutations de résistance.		45 000				
Wainberg M.	Canadian Institutes for Health Research	Individual/group Grant - Identification of Novel Targets To Interfere with HIV Reverse Transcriptase and Viral Multiplication.	157 919					
Wainberg M.	Canadian Institutes for Health Research	Methylation of HIV Viral Proteins as Key Steps in Viral Replication.	111 191					
Wainberg M.	Canadian Institutes for Health Research	Patterns of Drug Resistance and Viral Evolution in Patients Undergoing Primary HIV-1 Infection.	128 550					
Wainberg M.	Canadian Institutes for Health Research	Pro-active Intervention to Limit HIV Transmission among MSM Populations.	254 100					
Wainberg M.	Canadian Institutes for Health Research	Studies on HIV Integrase as Key Components of Effective Therapy: Molecular Pathogenesis Studies.	118 051					
Wainberg M.	Canadian Institutes for Health Research	Study of Complex Pharmacogenomicpharmacokinetics: Host-pathogen Interactions: Application to HIV Disease.		60 000				
Wainberg M.	Tibotec Pharmaceuticals Ltd	Selection of Resistance Against Etravirine (TMC-125) Using HIV Isolates of Different Subtypes.	34 310					
Wassmann S.	Canadian Institutes for Health Research	CRC/CIHR/Tier 2 - Enhancing the Healing of Diseased Blood Vessels		70 000				
Wassmann S.	Canada Foundation For Innovation	CFI - Mechanisms Involved in Endothelial Damage and Regeneration.	67 808					
Wassmann S.	Canadian Institutes for Health Research	Role of At1 Receptor Activation in Progenitor Cell Biology, Endothelial Regeneration, Atherosclerosis, Insulin Resistance, and Adipogenesis.	86 546					
Wolfson C.	Université de Montréal	Programme de gestion thérapeutique fondé sur des données probantes pour optimiser l'utilisation d'antidépresseurs: Étude pilote.	13 085					

Zaharatos J.	Health Sciences Centre	A 2008 23 Canadian Hospital National Surveillance Study to Evaluate the in Vitro Activities of Doripenem and Ceftobiprole Against Significant Clinical Pathogens Using Test Methodology.	2 500						
Zaharatos J.	Aaron Diamond Aids Research Cntr (ADARC)	David D - Harnessing Dendritic Cells and Innate Immune Activation Signals to Guide HIV Vaccine Development.	96 632						
JGH Foundation (including designated donations, bequests and endowments)									
Baron M.	Grouping of Canadian Individuals	Rheumatology Research.							52 813
Batist G.	Grouping of Canadian Individuals	Cytometry Fees.							47 500
Batist G.	Grouping of Canadian Individuals	Equipment Purchases.							535 000
Batist G.	Grouping of Canadian Individuals	Experimental Therapeutics.							847
Batist G.	Grouping of Canadian Individuals	Imaging Facility.							38 500
Batist G.	Grouping of Canadian Individuals	Oncology Research.							17 017
Batist G.	Grouping of Canadian Individuals	Research Pathology Facility.							80 000
Batist G.	Grouping of Canadian Individuals	Translational Research Center.							272 619
Becker R.	Grouping of Canadian Individuals	Internal Medicine Research.							167
Bergman H.	Grouping of Canadian Individuals	Geriatric Research.							35 598
Bergman H.	Grouping of Canadian Individuals	Geriatric Research.							34 023
Bergman H.	Grouping of Canadian Individuals	Memory Clinic.							58 783
Billick R.	Grouping of Canadian Individuals	Dermatology Research.							9 608
Caplan S.	Grouping of Canadian Individuals	Hematology Research.							210 711
Chertkow H.	Grouping of Canadian Individuals	Cognitive Research.							85
Cohen A.	Grouping of Canadian Individuals	Gastroenterology Research.							28 386
Cohen A.	Grouping of Canadian Individuals	Inflammatory Bowel Disease.							81 957
Dragatakis L.	Grouping of Canadian Comp. and Corp.	Cath Lab Education Fund.							3 400
Kahn A.	Grouping of Canadian Individuals	Insulin Fund.							4 022
Kahn S.	Grouping of Canadian Individuals	Thrombosis Clinic.							74 679
Karaplis A.	Grouping of Canadian Individuals	Dr. Karaplis-fracture Prevention Clinic							7 000
Langleben D.	Grouping of Canadian Individuals	Cardiology Research.							260 755
Langleben D.	Grouping of Canadian Individuals	Dr. Langleben -Ph Clinic							1 178
Langleben D.	Grouping of Canadian Individuals	Dr. Langleben-tietolman Cardiology Pop							39 093
Langleben D.	Grouping of Canadian Individuals	Echocardiology Research.							85
Langleben D.	Grouping of Canadian Individuals	Pencer Endowment.							32 921
Laporta D.	Grouping of Canadian Individuals	ICU Surgical Research.							12 737
Lipman M.	Grouping of Canadian Individuals	Hemodialysis Research.							18 073
Lipman M.	Grouping of Canadian Individuals	Renal Research.							204 061
Lipnowski M.	Grouping of Canadian Individuals	Dr. Lipnowski -Health Service							15 459
Michel C.	Grouping of Canadian Individuals	Inv-Dr. C. Michel-investigator							9
Miller M.	Grouping of Canadian Individuals	Infectious Diseases Research.							650
Miller W.	Grouping of Canadian Individuals	8th Int. Conf. of Differentiation Therapy - Montreal, QC, Oct. 3-6, 1999.							34 201
Panasci L.	Grouping of Canadian Individuals	Donations.							1 923
Pollak M.	Grouping of Canadian Individuals	Breast Cancer Research.							15 350
Portnoy J.	Grouping of Canadian Individuals	Dr. Portnoy-campagne Québécoise EAPSSS							110 000
Portnoy J.	Grouping of Canadian Individuals	Infectious Disease Research.							3 450
Schiffirin A.	Grouping of Canadian Individuals	Diabetes Research.							26 085
Schipper H.	Grouping of Canadian Individuals	Alzheimer's Research.							30
Schondorf R.	Grouping of Canadian Individuals	Autonomic Dysfunction Research.							100
Schweitzer M.	Grouping of Canadian Individuals	Cardiac Endocrinology Research.							4 346
Schweitzer M.	Grouping of Canadian Individuals	Cardiovascular Risk Research.							475
Schweitzer M.	Grouping of Canadian Individuals	Lipid Research.							55 000
Small D.	Grouping of Canadian Individuals	Pulmonary Research.							59 575
Sebag I.	Grouping of Canadian Individuals	Cardiology Research.							4 250
Szilagy A.	Grouping of Canadian Individuals	Fructose Study.							143
Therrien	Grouping of Canadian Individuals	Cardiology Research.							35 935
Trifiro M.	Grouping of Canadian Individuals	Endocrinology Research and Development.							106 478
Trifiro M.	Grouping of Canadian Individuals	Endocrinology Research.							6 351
Trifiro M.	Grouping of Canadian Individuals	Genetics Research.							1 529
Trifiro M.	Grouping of Canadian Individuals	Medical Genetics Research.							390
Wainberg M.	Grouping of Canadian Individuals	Aids Research.							1 491
Wainberg M.	Grouping of Canadian Individuals	Inv-Winberg Aids Project							17 356
Wainberg M.	Grouping of Canadian Individuals	Québec Conference.							22 000
Khanna	Grouping of Canadian Individuals	Skin Cancer Research Fund.							464
Schiffirin E.	Grouping of Canadian Individuals	Cardiovascular Prevention Centre.							10 868

Schiffrin E.	Grouping of Canadian Individuals	Dr. E. Schiffrin-dept. Medecine Endow							13 902
Schiffrin E.	Grouping of Canadian Individuals	Dr. E. Schiffrin-dept. Medecine Endow (Auxiliary)							1 609
Schiffrin E.	Grouping of Canadian Individuals	Phenotyping Facility.							42 500
Elizov M.	Grouping of Canadian Individuals	Dr. M. Elizov -Medical Residents							45 000
Macnamara E.	Grouping of Canadian Individuals	Dr. Macnamara E.-dep.of Med. Undergra. Ed							5 128
Kavan P.	Grouping of Canadian Individuals	Young Adult Program.							94 929
Jagoe T.	Grouping of Canadian Individuals	Cancer Nutrition Program CNRP.							201 166
Tamilia M	Grouping of Canadian Individuals	Thyroid Tumor Research.							400
Industrial Contracts									
Agulnik J.	Genetech Inc.	A Randomized, Double-blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab with or Without Apomab in Patients with Previously Untreated, Advance-stage Non-small Cell Lung Cancer.						30 347	
Agulnik J.	Genetech Inc.	A Randomized, Phase II, Multi-center, Double-blind, Placebo-controlled Study Evaluating the Safety and Activity of Metmab a Monoclonal Antagonist Antibody to The Receptor Met, Administered to Patients with Advanced Non-small Cell Lung Cancer.						14 471	
Agulnik J.	Amgen Canada Inc.	A Phase 1B/2 Study of AMG655 in Combination with Paclitaxel and Carboplatin for First-line Treatment of Advanced Non-small Cell Lung Cancer.						1 000	
Agulnik J.	Glaxosmithkline Inc. Canada	109493: a Double-blind, Randomized, Placebo-controlled Phase III Study to Assess the Efficacy of Recline-a3-a3+ Antigen-specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Mage-a3-positive Non-small Cell Lung Cancer.						7 996	
Assouline S.	Hoffman La Roche Ltd., Canada	Ph ³ -assouline S.-roche/prot N. BP 22333						4 000	
Baron M.	United Therapeutics Corporation	Distal-1: Digital Ischemic Lesion in Scleroderma Treated with Oral Treprostinil Diethanolamine (Protocol: TDE-DU-201)						5 901	
Baron M.	Actelion Pharmaceuticals Canada Inc.	A Two-stage Prospective Observational Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension.						7 307	
Blostein M.	Sanofi Aventis	Enoxa_I_02260-VTE Registry - National, Prospective, Observational Cohort Study of Venous Thromboembolism Management with the Low Molecular Weight Heparin, Enoxaparin, in the Outpatient Setting in Canada.						30 346	
Blostein M.	Bristol Myers Inc. Canada	A Phase 3, Active (Warfarin) Controlled, Randomized, Double-blind, Parallel-arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation. CV185030.						74 293	
Boutet K.	Bayer Inc. Health Care Division	Ph ³ boutet-pharbay 63-2521 Patent-2 Study						7 405	
Boutet K.	Millennium Pharmaceutical Inc.	Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral Bay 63-2521 (1 Mg, 1.5 Mg, 2 Mg, or 2.5 Mg Tid) in Patients with Symptomatic Pulmonary Arterial Hypertension. (Study 12934)						6 223	
Chertkow H.	National Institutes of Health (Usa) Ni	University of California, San Diego - A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of vitamin E and donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD).						12 638	
Cohen A.	Abbott Laboratories U.S.A.	A Multi-center, Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Ulcerative Colitis.						35 102	
Cohen A.		A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis.						46 482	
Cohen A.	Abbott Laboratories Canada	A phase IIB, multi-center, randomized, double-blind, parallel-group, placebo-controlled, dose ranging study comparing the efficacy, safety and pharmacokinetics of intravenous infusions of ABT-874 vs placebo in subjects with moderately to severely active Crohn's disease.						5 499	
Cohen A.	Millennium Pharmaceutical Inc.	Quintiles - A Phase 3, Randomized, Placebo-controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn's Disease.						8 215	

Cohen A.	Quintiles Inc.	A Phase 3, Randomized, Placebo-controlled, Blinded, Multicenter, Multiple Dose Study for the Induction and Maintenance of Clinical Response and Remission with Mln0002 in Patients with Moderate to Severe Ulcerative Colitis.				850		
Cohen A.	Schering Corporation Ltd. Usa	Screening for Hepatocellular Carcinoma.				172 840		
Cohen A.	ChemoCentryx (USA)	A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCS282-B in Subjects with Moderate to Severe Crohn's Disease.				2 500		
Cohen V	Novartis Pharma Canada Inc.	A Phase III, Randomized, Double-blind, Placebo-controlled Multi-center Study of Asa404 in Combination with Docetaxel In Second-line Treatment of Patients with Advanced or Metastatic (Stage III/IV) Non-small Cell Lung Cancer (NSCLC).				57 874		
CohenV.	Pharmaceutical Research Associates Inc.	A Multi-center Phase III Randomized, Double-blind, Placebo-controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease.				16 189		
Davidman M.	Astra Zeneca Inc.	A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events (AURORA) A double blind, randomised, multicentre, phase IIIb, parallel-group study to compare the effects of rosuvastatin (10mg oral) with placebo on assessment of survival and cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment				1 700		
Eisenberg M.	Pfizer Canada Inc.	Evaluation of Varenicline-(Champix™) in Smoking Cessation For Patients Post-acute Coronary Syndrome (Evita) Trial.				459 431		
Hilzenrat N.	ScheringPlough corporation	Education Grant.				3 948		
Hilzenrat N.	Hoffman La Roche Ltd., Canada	A Phase IV, Randomized, Multicenter, Efficacy and Safety Study Examining the Effect of Induction Dosing with the Combination of Peginterferon, Alfa-2A Ribavirin with Chronic Hepatitis C Infected with Hepatitis C Genotype 1.				12 000		
Hilzenrat N.		A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological...				5 250		
Hilzenrat N.		Improve - Individualized Management with Pegasys RBV Offering Viral Eradication.				3 900		
Hilzenrat N.	Glaxosmithkline Inc. Canada	TPL108390: Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects with Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy				7 409		
Hilzenrat N.	Schering Corporation Ltd. Canada	(SCH 54031) - PEG-Intron + as maintenance therapy vs an untreated control group in adult subjects with compensated cirrhosis (METAVIR F4), secondary to chronic Hepatitis C, who failed to respond to therapy with any alpha interferon plus ribavirin.				3 529		
Hilzenrat N.		Study P04257: Effect of Infliximab in Hepatitis-c Genotype 1 Patients with High TNF-alfa on the Efficacy of Pegylated Interferon-alfa 2/ribavirin Therapy.				22 025		
Hirsch A.	Icon Clinical Research	A Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ave5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy.				44 185		
Hirsch A.	Sunnybrook Health Sciences Centre (Toronto)	A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer. etc				3 500		
Kahn S.	Boehringer Ingelheim Canada Ltd.	Dabigatran "Re-medey" - a Phase III, Randomized, Multicenter, Double-blind, Parallel-group, etc				64 495		
Kahn S.	Boehringer Ingelheim Canada Ltd.	Re-cover II - Efficacy and Safety of Dabigatran 150 Mg Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (Phase III).				36 672		
Kahn S.	Boehringer Ingelheim Canada Ltd.	Re-cover Study - a Phase III, Randomized, Double-blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 Mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism				839		
Kahn S.	Sanofi Aventis	Recovery - Registry on Canadian Outpatients VTE Treatment (Recovery) - National, Prospective, Observational Cohort Study of VTE Management with the Low Molecular Weight Heparin, Enoxaprin, in the Outpatient Setting in Canada.				46 000		
Kahn S.		Thrombosis Fellowship.				60 000		

Kahn S.	Bristol Myers Inc. Canada	A Phase 3, Randomized, Double Blind, Parallel-group Multi-center Study of the Safety and Efficacy of Apixaban For Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization. CV185-036				1 302		
Kahn S.	Aventis Pharma Canada	A Double-blind Placebo-controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients with Prolonged Immobilization.				6 623		
Karaplis A.	Osta Biotechnologies Inc.	Evaluation of Novel CYP 24 Inhibitors and VDR Activators/CYP 24 Inhibitors in HYP and TRFGF23 Mouse Models.				20 000		
Langleben D.	Icos Corporation	An Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of the Phosphodiesterase Type 5 (Pde5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension.				2 716		
Langleben D.	Pfizer Canada Inc.	A Phase 2A, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Investigating the Dose-response of Pf00489791 on Acute Hemodynamics in Subjects with Idiopathic and Familial Pulmonary Arterial Hypertension.				7 599		
Langleben D.	Northern Therapeutics Inc.	The PHACET Trial, Pulmonary Hypertension Assessment of Cell Therapy.				16 667		
Miller M.	Glaxosmithkline Inc. Canada	HPV008 (580299/008) - A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals/HPV-16/18 VLP/AS04 vaccine persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0,1,6 month schedule in healthy females 15-25 years of age.				25 535		
Miller M.	Covance Canada Inc	Prospective Observational Study of Nosocomial Clostridium Difficile Toxin Antibody Concentrations, Incidence, and Recurrence.				161 224		
Miller M.	Health & Welfare Canada	Vancomycin-resistant Enterococci (VRE) Occurrence Report Protocol Canadian Nosocomial Infection Surveillance Program (CNISP).				33 454		
Miller M.	PPD Development LLC	E5564-G000-301 - ACCESS: A controlled comparison of eritoran tetrasodium and placebo in patients with severe sepsis				90 773		
Miller M.	BIOCRYST PHARMACEUTICALS	A Phase 3, Open Label, Randomized Study of the Antiviral Activity, Safety and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects with Confirmed or Suspected Influenza Infection.				63 374		
Miller M.	Optimer Pharmaceuticals, Inc.	A Multi-national, Multi-center, Double-blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200mg Par-101 Taken Q12h with 125mg Vancomycin Taken Q6h For Ten Days in Subjects with Clostridium Difficile-associated Diarrhea.				120 920		
Miller W.	Bayer Inc. Health Care Division	CRU - Phase 2 Study to Investigate the Efficacy and Safety Of Zk-epothilone (Zk-epo; Zk219477) in Patients with Metastatic Breast Cancer.				5 000		
Miller W.	Bristol Myers Inc. Canada	CRU - CA184-024 - a Multicenter, Randomized, Double-blind, Two-arm, Phase III Study in Patient with Untreated Stage III (Unresectable) or Stage IV Melanoma Receiving Dacarbazine plus 10mg/kg of Ipilimumab (MDX-010) Vs. Dacarbazine with Placebo.				3 448		
Miller W.	Merck Frosst	Defining Novel Mechanisms by Which Saha Induce Apoptosis In Cancer Cells.				36 250		
Palayew M.	Boehringer Ingelheim Canada Ltd.	A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled Bi 1744 Cl (5ug (2 Actuations of 2.5ug) And 10ug (2 Actuations of 5ug) Delivery				5 200		
Panasci L.	McGill University	Evaluation of DNA-PK Inhibitors in Malignant Human Cells. (Luitpold Pharmaceutical Inc.)				80 707		
Panasci L.	Novartis Pharma Canada Inc.	Nilotinib in Chronic Lymphocytic Leukemia (CLL).				60 652		
Pollak M.	Pfizer Canada Inc.	Pfizer Laboratory Service Agreement -Pollak				650 000		
Schweitzer M.	Merck Frosst Canada And Company	Niemann-pick C1-like 1 (NPC111) Structure Functions Analysis in Family of Disparate Ezetimibe Responders.				89 645		
Sheppard R.	Janssen-Ortho Inc.	Ascend-HF - Double-blind, Placebo-controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure.				28 325		
Sheppard R.	Novartis Pharma Canada Inc.	CSPP100A2368 - a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early after Ho				5 000		

Small D	Icon Clinical Research	A Randomized, Open-label, Phase 3 Trial of Nov-022 in Combination with Paclitaxel and Carboplatin Vs. Paclitaxel And Carboplatin Alone for the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC).				417		
Small D	Astra Zeneca Inc.	Asthma / Airways Centre Educational Grant.				35 000		
Small D	Aventis Behring Canada	A Prospective Study of Exercise Capacity and Functional Status in Patients Receiving Chemotherapy for Advance Stage 3A, 3B, and 4 Non-small Cell Lung Cancer.				403,65		
Tagalakis V	Pfizer Canada Inc.	Post-operative Venous Thromboembolism in Patients with Cancer: a Population Based Cohort Study (Protocol: WS462014). Investigator Initiated Research Agreement				55 000		
Trifiro M.	Sanofi Aventis	Diabetes Nurse Support Program				35 000		
Vaitekunas S	Hoffman La Roche Ltd., Canada	A Dose Ranging, Randomized, Double-blind, Parallel-group Placebo-controlled Multi-center of Ro5313534 Used as Add-on Donepezil Treatment in Patients with Mild to Moderate Symptoms of Alzheimer's Disease.				63 848		
Wainberg M.	Pfizer Canada Inc.	Does MVC Artificially Augment Plasma HIV Viremia.				32 500		
Wainberg M.	Gilead Sciences	Studies on Subtype C and Other Non-subtype B Reverse Transcriptase Enzymes.				39 113		
Wainberg M.	International Partnership For Microbicides	Microbicides 2007.				32 089		
Wainberg M.	Merck Frosst Canada and Company	HIV PCR Analysis of Tissue Samples for HIV DNA.				2 000		
CRU - Pollak M	Bayer Inc. Health Care Division	CRU - Phase I Open-label, Non-Randomized Non-placebo Study to Determine the Safety, Pharmacokinetics, and Tumor Response Profile of Sorafenib as continuous Dosing in Combination with Cyclophosphamide and Doxorubicin in Patients with Advanced, Refr				185 660		
	Hoffman La Roche Ltd., Canada	CRU - an Open-label, Multi-centre, Dose Escalating, Phase I/II Study to Investigate the Safety and Tolerability of Ro5072759 Given as Monotherapy in Patients with Cd20+ Malignant Disease.				35 026		
CRU - Pollak M	Pfizer U.S.A. Inc.	Ph-Pfizer-CRU-pollak-phase I Safety and				3 500		
	Wyeth Canada	CRU - a Phase 1/2 Study of SKI-606 in Philadelphia Chromosome Positive Leukemias.				62 610		
	Wyeth Canada	CRU - A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination with Exemestane Vs. Exemestane Alone as Second Line Therapy in Post-menopausal Women with Locally Advanced or Metastatic ER+/PGR+/ERBB2-breast Cancer.				1 270		
	Wyeth Canada	CRU - Open-label Extension Study to Assess the Safety of a Fixed Dose of Subcutaneous Methylnatrexone in Subjects With Advanced Illness and Opioid-induced Constipation.				1 790		
	Wyeth Canada	CRU - Randomized, Double-blind, Placebo-controlled Study of a Fixed Dose of Subcutaneous Methylnatrexone in Adults with Advanced Illness and Opioid-induced Constipation: Efficacy, Safety, and Additional Health Outcomes.				2 804		
	Glaxosmithkline Inc. Canada	CRU - a Study of Pazopanib Versus Sunitinib in the Treatment of Subjects with Locally Advanced And/or Metastatic Renal Cell Carcinoma.				28 211		
	Glaxosmithkline Inc. Canada	CRU - Tra105325: Extend (Eltrombopag Extended Dosing Study): an Extension Study of Eltrombopage Olamine (Sb-497115-gr) in Adults, with Idiopathic Thrombocytopenic Purpura (Itp), Previously Enrolled in an Eltrombopag Study.				10 049		
	Glaxosmithkline Inc. Canada	CRU - Tra108057 - an Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, with Chronic Idiopathic Thromocytopenic Purpura (ITP).				3 500		
	Glaxosmithkline Inc. Canada	CRU-Ipt109747: an Exploratory, Phase II Trial to Determine The Association of Lapatinib Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer.				16 643		
	Pfizer Canada Inc.	CRU - a Phase 2, Randomized,non-comparative, Two-arm Open Label, Multiple-center Study of Cp-751,871 in Combination with Docetaxel/prednisone in Chemotherapy - Naïve (Arm A) and Docetaxel/prednisone Refractory (Arm B) Patients with Hormone Insensi				56 215		
	Pfizer Canada Inc.	CRU - a SU011248 Expanded Access Protocol for Patients with Cytokine-refractory or Cytokine-intole				10 323		

	Pfizer Canada Inc.	CRU - a Two-arm Randomized Open Label Phase 2 Study of Cp-751,871 in Combination with Exemestane Versus Exemestane Versus Exemestane Alone as First Line Treatment For Postmenopausal Patients with Hormone Receptor Positive Advanced Breast Cancer.				123 619		
	Methylgene Inc.	CRU - a Phase II Study of Mg-0103 in Patients with Acute Myelogenous Leukemia/high Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/refractory Disease.				20 655		
	Methylgene Inc.	CRU - a Phase II Study of Mgcd0103 (Mg-0103) Given Three-times Weekly in Patients with Relapsed and Refractory Lymphoma.				41 362		
	GENZY	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study Confirming the Efficacy and Safety of Genz112638 in Patients with Gaucher Disease Type 1 - Genzyme CRU Assouline Gzgd02507				10 750		
	Université de Montréal	CRU - a Phase II Study of Ribavirin in Refractory or Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes.				44 161		
	Novartis Pharma Canada Inc.	A Canadian Open-label, Multicenter, Expanded Access Study Of Oral Amn 107 in Adult Patients with Imatinib (Glivec/gleevec) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase.				5 850		
	Novartis Pharma Canada Inc.	A Phase Ia/ii, Multi-center, Open-label Study of Hcd122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients with Advanced Non-hodgkin's Lymphoma Who Have Progressed after at Least Two Prior Therapies. (Chcd122a2103).				192 933		
	Novartis Pharma Canada Inc.	Clbh589b2201 - a Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-cell Lymphoma.				49 948		
	Novartis Pharma Canada Inc.	CRU - an Open-label, Multicenter Phase 1 Study Investigating the Combination of Rad001, Cetuximab and Irinotecan as Second-line Therapy after Folfox (Or Xelox) Plus Bevacizumab (If Given as Part of Local Standard Practice) in Patients with Metasta				579		
	Novartis Pharma Canada Inc.	CRU - CLBH589b2204 - a Phase IB/IIA, Trial of LBH589 in Combination with Trastuzumab in Adult Female Patients with HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy with Trastuzumab.				12 116		
	Novartis Pharma Canada Inc.	CRU - Folfox (Or Xelox) - a Single, Arm, Multicenter Phase II Study of RAD001 in Patients with Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy with an Anti-EGFR Antibody (If Appropriate), Bevacizumab, Fluorop				2 886		
	Novartis Pharma Canada Inc.	Randomized, Open-label, Phase 3 Trial of Erlotinib Alone Or in Combination with CP-751,871 in Patients with Advanced Non-small Cell Lung Cancer of Non-adenocarcinoma Histology.				29 501		
	Novartis Pharma Canada Inc.	Randomized, Open-label, Phase III Trial of Cp-751,871 in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin in Patients with Non-small Cell Lung Cancer.				2 000		
	Astra Zeneca Inc.	CRU - a Phase I, Open-label, Non-randomized Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (Azd2171, Recept), in Patients with Advanced Solid Tumors.				118 000		
	Aegera Theapeutics Inc	AEG35156-204: a Phase 1-2, Multicenter, Open-label Study of the X-linked Inhibitor of Apoptosis (Xiap) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, and Indolent B Cell Lymphomas.				91 109		
	Glaxosmithkline Inc. Usa	CRU - a Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women With Early-stage Erbb2 Overexpressing Breast Cancer.				2 421		
	Oncozyme Pharma Inc.	CRU - a Phase I/II Clinical Study Using Pentamidine in Patients with Metastatic Colon Cancer Undergoing Standard Folinic Acid (Leucovorin), 5-fluorouracil, and Oxaliplatin (Folfox) Chemotherapy as Second-line Treatment.				96 719		
	GW phmaraceuticals pic	A Double-blind, Randomized, Placebo-controlled, Parallel Group Dose-range Exploration Study of Sativex in Relieving Pain in Patients with Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.				15 260		

	Medarex Inc.	CRU - a Randomized, Double-blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with A Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-a*0201-positive Patients with Previously Treated Unresectable Stage				25 319		
	Ziopharm inc.	CRU - Phase I Study of Oral Zio-101-c in Advanced Solid Tumors.				77 688		
	Zymogenetics	CRU - a Phase ½, Open-label, Dose-escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin-21 Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma.				30 436		
	Wex Pharmaceuticals Inc	CRU - a Multi-centre, Open-label, Long-term Efficacy and Safety Continuation Study of Subcutaneous Tetrodotoxin (Tectin) for Moderate to Severe Cancer-related Pain.				41 436		
	Wex Pharmaceuticals Inc	CRU - a Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy And Safety of Subcutaneous Tetrotoxin (Tectin) for Moderate to Severe Inadequately Controlled Cancer-related Pain.				75 511		
	Proteolix Inc.	CRU - an Open Label, Single Arm, Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (Px-171-003).				21 618		
Clinical Research Awards								
Agulnik J	Department of Medicine, JGH	Utility of different non-surgical biopsies in the genetic profiling and cellular differentiation of non-small cell lung cancer (NSCLC)					8 000	
Assouline S	Department of Medicine, JGH	Combination of imatinib and chlorambucil for the treatment of patients with relapsed chronic lymphocytic leukemia and Efficacy of ribavirin for the treatment of acuter myeloid leukemia subtypes M4 and M5					11 333	
Baron M	Department of Medicine, JGH	Statins in scleroderma					11 333	
Blostein M	Department of Medicine, JGH	1.TIPPS (Thrombophilia in Pregnancy Prophylaxis Study): A multicenter, multinational randomised control trial of prophylactic low molecular weight heparin (LMWH) in high risk pregnant thrombophilic women.					8 000	
		2.A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Atrial Fibrillation						
		3.A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)						
Dascal A	Department of Medicine, JGH	C difficile, pandemic preparedness and immune building design					3 333	
Greenaway C	Department of Medicine, JGH	"The Burden of Infectious Diseases in Immigrants and Refugees: Reviewing the Evidence"					8 000	
Kader T	Department of Medicine, JGH	Cpeptide levels and how they predict insulin response in type two diabetic patients who have failed oral agents					11 333	
Miller M	Department of Medicine, JGH	Household transmission of C. difficile					11 333	
Sharon N	Department of Medicine, JGH	The Relationship Between Peritoneal Transport Status and Vitamin D Deficiency Among Peritoneal Dialysis Patients					8 000	
Rudski L	Department of Medicine, JGH	echocardiography-based research on the right heart					11 333	
Schweitzer M	Department of Medicine, JGH	Atorvastatin treatment in abdominal aortic aneurysm (AAA)					11 333	
Szilagyi A	Department of Medicine, JGH	Possible role of lactose digestion and maldigestion in risk modification of multiple diseases and their impact on the geographical distribution of certain Western diseases					3 333	
TOTALS			18 833 954	1 510 485	-	4 681 619	106 664	3 100 159